Most Read Articles
3 days ago
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course

Genetic testing vital for lung cancer diagnosis, management

Dr Joslyn Ngu
04 Dec 2017

Genetic testing has changed the landscape of lung cancer and every patient needs to undergo testing, says a specialist.

Testing allows for the determination of actionable genetic alterations in lung cancer and is vital as it allows better treatment, said clinical oncologist Dr Tho Lye Mun. Research has found that patients with an oncogenic driver mutation who were given targeted therapy had better survival rate than those who did not receive targeted therapy and patients without an oncogenic driver. [JAMA 2014;311(19):1998–2006]

With the advancement in genetic testing, diagnosing lung cancer now involves an additional step. Besides conventional diagnosis using morphological or basic immunohistochemical features, for example to differentiate small cell lung cancer versus non-small cell lung carcinoma (NSCLC), identifying actionable genetic alterations such as EGFR, ALK , ROS-1 and PDL-1 should also be part of routine lung cancer diagnosis, said Tho.

The ability to classify patients in a more precise manner allows for more appropriate therapeutic strategy and for patients to receive the maximum effect of molecularly targeted drugs or immunotherapy. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course